ReviewCell death & disease2014
Koschei the immortal and anti-aging drugs.
Review in Cell death & disease, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Review
- Immunomodulatory effects of cannabinoids against viral infections: a review of its potential use in SARS-CoV2 infection.Virusdisease · 2024Review
- The hyperfunction theory: An emerging paradigm for the biology of aging.Ageing research reviews · 2022Review
- Article
- The goal of geroscience is life extension.Oncotarget · 2021Article
- Aging delay: of mice and men.Acta bio-medica : Atenei Parmensis · 2021Article
- Potential Antiaging Effects of DLBS1649, aJournal of experimental pharmacology · 2021Article
- Article
- Rapamycin for longevity: opinion article.Aging · 2019Article
- The mystery of the ketogenic diet: benevolent pseudo-diabetes.Cell cycle (Georgetown, Tex.) · 2019Article
- Fasting and rapamycin: diabetes versus benevolent glucose intolerance.Cell death & disease · 2019Review
- Article
- Multi-dimensional computational pipeline for large-scale deep screening of compound effect assessment: an in silico case study on ageing-related compounds.NPJ systems biology and applications · 2019Article
- Disease or not, aging is easily treatable.Aging · 2018Article
- Article
- From rapalogs to anti-aging formula.Oncotarget · 2017Review
- Increased Arf/p53 activity in stem cells, aging and cancer.Aging cell · 2017Review
- mTOR Inhibition Rejuvenates the Aging Gingival Fibroblasts through Alleviating Oxidative Stress.Oxidative medicine and cellular longevity · 2017Article
- Gerosuppression by pan-mTOR inhibitors.Aging · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Slavic folklore, Koschei the Immortal was bony, thin and lean. Was his condition caused by severe calorie restriction (CR)? CR deactivates the target of rapamycin pathway and slows down aging. But the life-extending effect of severe CR is limited by starvation. What if Koschei's anti-aging formula included rapamycin? And was rapamycin (or another rapalog) combined with commonly available drugs such as metformin, aspirin, propranolol, angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.